{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:07:08Z","timestamp":1790352428387,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Stage IVB esophageal cancer typically has a poor prognosis; patients with non-regional lymph-node metastasis (cM1 LYM) but no organ metastasis generally fare better. However, comprehensive reports on treatment outcomes are limited. We included 158 patients with esophageal squamous cell carcinoma (ESCC) and cM1 LYM without organ metastasis treated at our institute between October 2006 and November 2022; their treatment outcomes were assessed, and prognostic factors were evaluated. The 3-year overall survival (OS) rates for all patients and those treated with surgery, chemoradiotherapy, chemotherapy, or palliative radiotherapy were 43.7%, 60.7%, 38.5%, 22.4%, and 20.0%, respectively. Surgery or chemoradiotherapy significantly improved OS compared to chemotherapy. Univariate and multivariate analyses identified significant OS prognostic factors: Eastern Cooperative Oncology Group performance status (ECOG PS) (1\/2 vs. 0), type of cM1 LYM areas (two areas vs. thoracic area), and clinical response (stable\/progressive disease vs. complete\/partial response). In the subgroup receiving surgery or chemoradiotherapy, both analyses identified ECOG PS (1\/2 vs. 0) and clinical response (stable\/progressive disease vs. complete\/partial response) as prognostic factors for OS. ESCC patients with cM1 LYM without organ metastasis had relatively good survival; those with good PS and a favorable clinical response especially achieved long-term survival. Because patients who underwent surgery or chemoradiotherapy had significantly better OS than those treated with chemotherapy, appropriate localized treatment might be necessary even in these cases.<\/jats:p>","DOI":"10.1093\/dote\/doaf095","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:09:48Z","timestamp":1760530188000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment outcomes of esophageal squamous cell carcinoma with cM1 lymph node without organ metastasis"],"prefix":"10.1093","volume":"38","author":[{"given":"Manato","family":"Ohsawa","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-8019","authenticated-orcid":false,"given":"Yoichi","family":"Hamai","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Emi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Ibuki","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Hirohata","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-8566","authenticated-orcid":false,"given":"Nao","family":"Kitasaki","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-3828","authenticated-orcid":false,"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University , Hiroshima 734-0037,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2025103109592607400_ref1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2025103109592607400_ref2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","article-title":"Epidemiology of esophageal squamous cell carcinoma","volume":"154","author":"Abnet","year":"2018","journal-title":"Gastroenterology"},{"key":"2025103109592607400_ref3","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2025103109592607400_ref4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025103109592607400_ref5","volume-title":"International Union Against Cancer (UICC): TNM Classification of Malignant Tumors","author":"Brierley","year":"2016","edition":"8th"},{"key":"2025103109592607400_ref6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/JTO.0b013e3182397751","article-title":"Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis","volume":"7","author":"Dubecz","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2025103109592607400_ref7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal society: part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"2025103109592607400_ref8","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"key":"2025103109592607400_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100426","article-title":"Nonregional lymph nodes as the only metastatic site in stage IV esophageal cancer","volume":"3","author":"Zhan","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2025103109592607400_ref10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(17)30181-X","article-title":"Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial","volume":"18","author":"Kudo","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025103109592607400_ref11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025103109592607400_ref12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"2025103109592607400_ref13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"2025103109592607400_ref14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/01.sla.0000118562.97742.29","article-title":"Improved survival for patients with upper and\/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection","volume":"239","author":"Igaki","year":"2004","journal-title":"Ann Surg"},{"key":"2025103109592607400_ref15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10388-022-00977-8","article-title":"Significance of dissection in each regional lymph-node station of esophageal cancer based on efficacy index and recurrence patterns after curative esophagectomy","volume":"20","author":"Kanemura","year":"2023","journal-title":"Esophagus"},{"key":"2025103109592607400_ref16","first-page":"3741","article-title":"Clinical outcomes of resectable esophageal cancer with supraclavicular lymph node metastases treated with curative intent","volume":"37","author":"Honma","year":"2017","journal-title":"Anticancer Res"},{"key":"2025103109592607400_ref17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11748-017-0802-0","article-title":"Successful resection after neoadjuvant chemotherapy for esophageal cancer with posterior thoracic paraaortic lymph node metastasis: a case report and literature review","volume":"65","author":"Shishido","year":"2017","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2025103109592607400_ref18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.18926\/AMO\/61211","article-title":"Bilateral approach for thoracoscopic esophagectomy in a patient with esophageal cancer and solitary posterior thoracic Para-aortic lymph node metastasis","volume":"74","author":"Itazaki","year":"2020","journal-title":"Acta Med Okayama"},{"key":"2025103109592607400_ref19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.amjsurg.2006.06.047","article-title":"Surgical outcome after the clearance of abdominal metastatic lymph nodes in 138 patients with thoracic esophageal carcinoma","volume":"193","author":"Shimada","year":"2007","journal-title":"Am J Surg"},{"key":"2025103109592607400_ref20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/bjs.8967","article-title":"Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction","volume":"100","author":"Mine","year":"2013","journal-title":"Br J Surg"},{"key":"2025103109592607400_ref21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2025103109592607400_ref22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"key":"2025103109592607400_ref23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00330-023-10020-8","article-title":"Radiomics and dosiomics for predicting complete response to definitive chemoradiotherapy patients with oesophageal squamous cell cancer using the hybrid institution model","volume":"34","author":"Kawahara","year":"2024","journal-title":"Eur Radiol"},{"key":"2025103109592607400_ref24","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.athoracsur.2015.02.042","article-title":"Results of neoadjuvant chemoradiotherapy with docetaxel and 5-fluorouracil followed by esophagectomy to treat locally advanced esophageal cancer","volume":"99","author":"Hamai","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"2025103109592607400_ref25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jrr\/rry047","article-title":"Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma","volume":"59","author":"Murakami","year":"2018","journal-title":"J Radiat Res"},{"key":"2025103109592607400_ref26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/CMAR.S150350","article-title":"Sites of metastasis and overall survival in esophageal cancer: a population-based study","volume":"Volume 9","author":"Wu","year":"2017","journal-title":"Cancer Manag Res"},{"key":"2025103109592607400_ref27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ags3.12623","article-title":"Defining conversion therapy for esophageal squamous cell carcinoma","volume":"7","author":"Matsuda","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"key":"2025103109592607400_ref28","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1245\/s10434-024-14960-3","article-title":"Clinical impact of conversion surgery after induction therapy for esophageal cancer with synchronous distant metastasis: a multi-institutional retrospective study","volume":"31","author":"Sugimura","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2025103109592607400_ref29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1245\/s10434-024-16196-7","article-title":"Safety and efficacy of conversion therapy after systemic chemotherapy in advanced esophageal cancer with distant metastases: a multicenter retrospective observational study","volume":"32","author":"Tsuji","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2025103109592607400_ref30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10147-015-0896-2","article-title":"Chemoradiotherapy for T4 and\/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan","volume":"21","author":"Jingu","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2025103109592607400_ref31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1245\/s10434-023-14562-5","article-title":"Significance of surgery for resectable M1 lymph node metastases without organ metastasis in esophageal carcinoma in the era of neoadjuvant treatment","volume":"31","author":"Igaue","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2025103109592607400_ref32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2023.02.015","article-title":"Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe","volume":"185","author":"Kroese","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025103109592607400_ref33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/icvts\/ivaa116","article-title":"Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data","volume":"31","author":"Schizas","year":"2020","journal-title":"Interact Cardiovasc Thorac Surg"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/5\/doaf095\/65048492\/doaf095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/5\/doaf095\/65048492\/doaf095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:59:32Z","timestamp":1761919172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doaf095\/8307342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doaf095","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,1]]},"article-number":"doaf095"}}